Literature DB >> 2019365

Anti-neutrophil cytoplasmic antibodies in ulcerative colitis. Comparison with other colitides/diarrheal illnesses.

R H Duerr1, S R Targan, C J Landers, L R Sutherland, F Shanahan.   

Abstract

Previous studies from this laboratory showed that serum anti-neutrophil cytoplasmic antibodies, distinct from those associated with active Wegener's granulomatosis, are present in the majority of patients with ulcerative colitis. In this study, the specificity of anti-neutrophil cytoplasmic antibodies for ulcerative colitis as compared with other colitides and diarrheal illness was determined. In a blinded study, test samples of serum were screened for anti-neutrophil immunoglobulin G in a fixed neutrophil enzyme-linked immunosorbent assay. Levels of neutrophil binding by immunoglobulin G and titers of anti-neutrophil immunoglobulin G in sera from patients with ulcerative colitis and patients with ulcerative colitis post colectomy were each significantly greater than the levels and titers for normal controls and patients with a variety of other colitides and diarrheal illnesses. Levels of neutrophil binding for colonic Crohn's disease, bacterial/amoebic colitis, the irritable bowel syndrome with diarrhea, and other miscellaneous diarrheal illnesses were not significantly different than the levels for normal controls. Although the levels of binding for collagenous colitis were significantly less than the levels for ulcerative colitis, they were significantly greater than the levels for normal controls. Patterns of neutrophil binding by serum samples that were positive in the enzyme-linked immunosorbent assay were determined by indirect immunofluorescence. Perinuclear staining was the predominant pattern shown by sera from patients with ulcerative colitis. The combination of a positive value in the enzyme-linked immunosorbent assay and a perinuclear immunofluorescence pattern was 60% sensitive and 94% specific for ulcerative colitis. It is concluded that anti-neutrophil cytoplasmic antibodies in ulcerative colitis are not simply an epiphenomenon related to inflammation of the colon. Identification of the antigen(s) to which these autoantibodies are directed may facilitate understanding of the underlying immune response and may allow development of an assay that is more sensitive and specific for ulcerative colitis.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2019365     DOI: 10.1016/0016-5085(91)90657-7

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  67 in total

1.  Familial expression of anti-Saccharomyces cerevisiae mannan antibodies in affected and unaffected relatives of patients with Crohn's disease.

Authors:  C L Sutton; H Yang; Z Li; J I Rotter; S R Targan; J Braun
Journal:  Gut       Date:  2000-01       Impact factor: 23.059

Review 2.  Serologic testing in inflammatory bowel disease: its value in indeterminate colitis.

Authors:  K A Papadakis; S R Targan
Journal:  Curr Gastroenterol Rep       Date:  1999-12

Review 3.  Are anti-neutrophil cytoplasmic antibodies (ANCA) clinically useful in inflammatory bowel disease (IBD)?

Authors:  C Roozendaal; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1999-05       Impact factor: 4.330

4.  Lymphocytic and Collagenous Colitis.

Authors: 
Journal:  Curr Treat Options Gastroenterol       Date:  2000-06

Review 5.  Evaluation of inflammatory activity in Crohn's disease and ulcerative colitis.

Authors:  Eduardo Garcia Vilela; Henrique Osvaldo da Gama Torres; Fabiana Paiva Martins; Maria de Lourdes de Abreu Ferrari; Marcella Menezes Andrade; Aloísio Sales da Cunha
Journal:  World J Gastroenterol       Date:  2012-03-07       Impact factor: 5.742

Review 6.  Current concept of pathophysiological understanding and natural course of ulcerative colitis.

Authors:  Martin H Holtmann; Peter R Galle
Journal:  Langenbecks Arch Surg       Date:  2004-02-04       Impact factor: 3.445

7.  Anti-neutrophil cytoplasmic autoantibodies in inflammatory bowel diseases (IBD).

Authors:  T Nakato; M Fukushima; H Yamamoto
Journal:  Gastroenterol Jpn       Date:  1992-10

8.  Current and future role of serogenomics in ulcerative colitis.

Authors:  Mark H Flasar; Raymond K Cross; David B Doman
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-11

9.  Boswellia serrata extract for the treatment of collagenous colitis. A double-blind, randomized, placebo-controlled, multicenter trial.

Authors:  Ahmed Madisch; Stephan Miehlke; Otto Eichele; Jenny Mrwa; Birgit Bethke; Eberhard Kuhlisch; Elke Bästlein; Georg Wilhelms; Andrea Morgner; Bernd Wigginghaus; Manfred Stolte
Journal:  Int J Colorectal Dis       Date:  2007-09-02       Impact factor: 2.571

10.  Autoimmunity to tropomyosin isoforms in ulcerative colitis (UC) patients and unaffected relatives.

Authors:  L Biancone; G Monteleone; R Marasco; F Pallone
Journal:  Clin Exp Immunol       Date:  1998-08       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.